PH12021550003A1 - Biaryl ether-type quinazoline derivatives - Google Patents

Biaryl ether-type quinazoline derivatives

Info

Publication number
PH12021550003A1
PH12021550003A1 PH12021550003A PH12021550003A PH12021550003A1 PH 12021550003 A1 PH12021550003 A1 PH 12021550003A1 PH 12021550003 A PH12021550003 A PH 12021550003A PH 12021550003 A PH12021550003 A PH 12021550003A PH 12021550003 A1 PH12021550003 A1 PH 12021550003A1
Authority
PH
Philippines
Prior art keywords
type
quinazoline derivatives
biaryl ether
exon
pharmaceutically acceptable
Prior art date
Application number
PH12021550003A
Other languages
English (en)
Inventor
Kenichi Yoshida
Kosuke Takeuchi
Hidekazu Inoue
Hideaki Kageji
Takayuki Momose
Keisuke Yoshida
Takeshi Jimbo
Akiko Egami
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of PH12021550003A1 publication Critical patent/PH12021550003A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PH12021550003A 2018-07-04 2021-01-03 Biaryl ether-type quinazoline derivatives PH12021550003A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018127829 2018-07-04
PCT/JP2019/026483 WO2020009156A1 (ja) 2018-07-04 2019-07-03 ビアリールエーテル型キナゾリン誘導体

Publications (1)

Publication Number Publication Date
PH12021550003A1 true PH12021550003A1 (en) 2021-09-20

Family

ID=69059535

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021550003A PH12021550003A1 (en) 2018-07-04 2021-01-03 Biaryl ether-type quinazoline derivatives

Country Status (15)

Country Link
US (1) US20230025510A1 (cg-RX-API-DMAC7.html)
EP (1) EP3822263A4 (cg-RX-API-DMAC7.html)
JP (1) JP7288904B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210029165A (cg-RX-API-DMAC7.html)
CN (1) CN112334460A (cg-RX-API-DMAC7.html)
AU (1) AU2019297889A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020027064A2 (cg-RX-API-DMAC7.html)
CA (1) CA3105602A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021000800A2 (cg-RX-API-DMAC7.html)
IL (1) IL279858A (cg-RX-API-DMAC7.html)
MX (1) MX2021000014A (cg-RX-API-DMAC7.html)
PH (1) PH12021550003A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202013218QA (cg-RX-API-DMAC7.html)
TW (1) TW202012391A (cg-RX-API-DMAC7.html)
WO (1) WO2020009156A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020262998A1 (ko) * 2019-06-26 2020-12-30 한미약품 주식회사 항 종양 활성을 갖는 신규 퀴나졸린 유도체 및 이를 포함하는 약학 조성물
KR102887500B1 (ko) 2020-08-10 2025-11-17 아비스코 테라퓨틱스 컴퍼니 리미티드 Egfr 억제제 및 이의 제조방법 및 응용
CN115803326B (zh) * 2020-11-23 2024-03-26 上海和誉生物医药科技有限公司 Egfr抑制剂及其制备方法与在药学上的应用
CN113264888A (zh) 2021-03-04 2021-08-17 江苏康可得生物技术股份有限公司 酪氨酸激酶抑制剂及其药物应用
JP7598180B2 (ja) * 2021-03-19 2024-12-11 北京賽特明強医薬科技有限公司 キナゾリン系化合物、キナゾリン系化合物の組成物及び応用
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
EP4476211A4 (en) * 2022-02-09 2026-02-25 Enliven Inc ACYLIC HETEROCYCLIC QUINAZOLINE DERIVATIVES USED AS ERBB2 INHIBITORS
TW202404590A (zh) * 2022-04-05 2024-02-01 美商纜圖藥品公司 Egfr抑制劑
CN117384162A (zh) * 2022-05-17 2024-01-12 浙江文达医药科技有限公司 选择性her2抑制剂
WO2025167927A1 (zh) * 2024-02-05 2025-08-14 苏州韬略生物科技股份有限公司 三取代喹唑啉衍生物及其酸加成盐及其药物组合物和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100503580C (zh) * 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
EP1636195A1 (en) * 2003-05-27 2006-03-22 Pfizer Products Inc. Quinazolines and pyrido[3,4-d]pyrimidines as receptor tyrosine kinase inhibitors
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
WO2013173254A1 (en) * 2012-05-14 2013-11-21 Dawei Zhang Bicyclic compounds as kinases inhibitors
CN103965120B (zh) * 2013-01-25 2016-08-17 上海医药集团股份有限公司 喹啉及喹唑啉衍生物、制备方法、中间体、组合物及应用
BR112019010020A2 (pt) * 2016-11-17 2019-08-20 Univ Texas compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
WO2020262998A1 (ko) * 2019-06-26 2020-12-30 한미약품 주식회사 항 종양 활성을 갖는 신규 퀴나졸린 유도체 및 이를 포함하는 약학 조성물

Also Published As

Publication number Publication date
TW202012391A (zh) 2020-04-01
WO2020009156A1 (ja) 2020-01-09
BR112020027064A2 (pt) 2021-05-25
CO2021000800A2 (es) 2021-02-08
EP3822263A1 (en) 2021-05-19
MX2021000014A (es) 2021-03-09
KR20210029165A (ko) 2021-03-15
CN112334460A (zh) 2021-02-05
JPWO2020009156A1 (ja) 2021-07-15
SG11202013218QA (en) 2021-02-25
IL279858A (en) 2021-03-01
JP7288904B2 (ja) 2023-06-08
CA3105602A1 (en) 2020-01-09
EP3822263A4 (en) 2022-03-16
US20230025510A1 (en) 2023-01-26
AU2019297889A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
MX2021000014A (es) Derivados de quinazolina tipo eter biarilico.
GEAP202215535A (en) Compounds
NZ723151A (en) 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom
MX2019006079A (es) Derivados de oxoisoquinolina novedosos.
JOP20220142B1 (ar) مثبطات kras g12c
MX2022006609A (es) Compuesto de quinazolina que contiene anillo espiro.
PH12021551167A1 (en) New heterocyclic compounds
PH12022551574A1 (en) Egfr inhibitors
EA202191051A1 (ru) Ингибитор аврора-киназы a для применения для лечения нейробластомы
MX418519B (es) Inhibidores selectivos de jak1
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
TR201903322T4 (tr) Kinaz inhibisyonu için heteroaril bileşikleri.
CY1125335T1 (el) Ετεροαρυλικες ενωσεις ως αναστολεας κινασης
PH12021553233A1 (en) Imidazopyrimidines as eed inhibitors and the use thereof
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
JOP20190073A1 (ar) مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20
MX2020012980A (es) Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina.
MX2022000318A (es) Indanos como inhibidores de pd-l1.
PH12022551241A1 (en) Egfr inhibitors
PH12021551407A1 (en) Novel hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof
PH12020500408A1 (en) Cycloolefin substituted heteroaromatic compounds and their use
SA521421262B1 (ar) مشتق أمين جديد حلقي غير متجانس وتركيبة صيدلانية تشتمل عليه
AU2018284249A1 (en) Aminothiazole compounds as protein kinase inhibitors
NZ779146A (en) Cyclic molecules as bruton’s tyrosine kinase inhibitor